Sovateltide

ApprovedPeptide

PPharmazz, Inc.

Sovateltide is one of 73 small molecule programs targeting Encephalopathy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EncephalopathyActive, not recruiting

Acute Ischemic StrokeRecruiting

Ischemic StrokeActive, not recruiting

EncephalopathyPhase 2

Active, not recruiting

Acute Ischemic StrokePhase 3

Recruiting

Ischemic StrokeApproved

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Sovateltide

PPharmazz, Inc.

Approved

1 2

Proamatine

Takeda

Preclinical

2 3

Repatha

Amgen

Preclinical

2 4

Levaquin

WWim Janssens

Preclinical

3 5

Tylenol

KKenvue Brands

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Urokinase

Mmedac GmbH

Preclinical

3 10

Drug Therapy

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Acute Ischemic Stroke

NCT05691244

Phase 2Recruiting

Encephalopathy

NCT05514340

Clinical

Trials by Indication[1]

Encephalopathy1 trial

Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy

Recruiting·PPharmazz, Inc.·Phase 2·NCT05514340·40 enrolled

Ischemic stroke1 trial

Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Recruiting·PPharmazz, Inc.·Phase 4·NCT05955326·160 enrolled

Acute Ischemic Stroke1 trial

A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.

Recruiting·PPharmazz, Inc.·Phase 3·NCT05691244·514 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Sovateltide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sovateltide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sovateltide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pharmazz, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Approved[1]
Company: PPharmazz, Inc.

Sovateltide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Encephalopathy1 trial

Ischemic stroke1 trial

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News